Recent News

• 03.04.2025 - Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
• 03.04.2025 - Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
• 03.04.2025 - Plus Therapeutics Secures Private Placement of Approximately $15 Million in Gross Proceeds
• 02.26.2025 - Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
• 02.26.2025 - Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
• 02.26.2025 - Plus Therapeutics Advances Lead Drug Rhenium (186Re) Obisbemeda for Patients with Leptomeningeal Metastases
• 02.24.2025 - Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
• 02.24.2025 - Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
• 02.24.2025 - Plus Therapeutics Announces Leadership Appointments for its CNSide Diagnostics Subsidiary
• 02.20.2025 - Plus Therapeutics Appoints Dr. Michael Rosol as Chief Development Officer

Recent Filings

• 03.04.2025 - 8-K Current report
• 03.04.2025 - 424B3 Prospectus [Rule 424(b)(3)]
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities
• 02.20.2025 - 4 Statement of changes in beneficial ownership of securities